NEW YORK – Krystal Biotech has discontinued a Phase I/II clinical trial evaluating an injected version of its gene therapy KB707 in locally advanced or metastatic solid tumors, including melanoma.

The antisense oligonucleotide is a prophylactic treatment for preventing swelling attacks due to hereditary angioedema.

A lab's interpretation that an STK11 variant of uncertain significance is likely pathogenic supports a young woman's ...

ALX hopes to gain insights by tracking EGFR expression in a new trial of ALX2004 and to identify best responders using CD47 expression in a trial of evorpacept.

The firm is advancing ELI-002 after seeing a positive Phase I readout this month and is expecting initial results from a randomized Phase II study this year.